Related Experiment Video
Updated: Aug 20, 2026
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models
Laifong Lee1, Paul Sudentas, Brian Donohue
1Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Abstract:
Tuberous sclerosis complex (TSC) is a familial tumor disorder for which there is no effective medical therapy. Disease-causing mutations in the TSC1 or TSC2 gene lead to increased mammalian target of rapamycin (mTOR) kinase activity in the conserved mTOR signaling pathway, which regulates nutrient uptake, cell growth, and protein translation. The normal function of TSC1 and TSC2 gene products is to form a complex that reduces mTOR kinase activity. Thus, mTOR kinase inhibition may be a useful targeted therapeutic approach. Elevated interferon-gamma (IFN-gamma) expression is associated with decreased severity of kidney tumors in TSC patients and mouse models; therefore, IFN-gamma also has therapeutic potential. We studied cohorts of Tsc2+/- mice and a novel mouse model of Tsc2-null tumors in order to evaluate the efficacy of targeted therapy for TSC. We found that treatment with either an mTOR kinase inhibitor (CCI-779, a rapamycin analog) or with IFN-gamma reduced the severity of TSC-related disease without significant toxicity. These results constitute definitive preclinical data that justify proceeding with clinical trials using these agents in selected patients with TSC and related disorders.
Insights
Tuberous sclerosis complex (TSC) treatments targeting mTOR kinase or using interferon-gamma show promise. These therapies reduced disease severity in mouse models, supporting potential clinical trials for TSC patients.
Area of Science:
- Genetics and Molecular Biology
- Oncology
- Pharmacology
Background:
- Tuberous sclerosis complex (TSC) is an inherited tumor disorder lacking effective treatments.
- Mutations in TSC1 or TSC2 genes dysregulate the mTOR signaling pathway, crucial for cell growth.
- mTOR kinase activity is elevated in TSC, suggesting it as a therapeutic target.
Purpose of the Study:
- To evaluate the efficacy of targeted therapies for TSC using mouse models.
- To investigate the therapeutic potential of mTOR kinase inhibitors and interferon-gamma (IFN-gamma).
Main Methods:
- Studied Tsc2+/- mice and a novel Tsc2-null tumor mouse model.
- Administered an mTOR kinase inhibitor (CCI-779, a rapamycin analog).
- Administered interferon-gamma (IFN-gamma).
Main Results:
- Both mTOR kinase inhibition and IFN-gamma treatment reduced TSC-related disease severity.
- Treatments were found to be well-tolerated with no significant toxicity observed.
- Preclinical data strongly support the efficacy of these targeted agents.
Conclusions:
- mTOR kinase inhibitors and IFN-gamma represent viable targeted therapeutic strategies for TSC.
- These findings provide a strong rationale for initiating clinical trials in TSC patients.
- Targeted therapies offer a promising new avenue for managing TSC and related disorders.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...